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3UHYDOHQFH DQG 3UHGLFWLRQ RI2EVWUXFWLYH &RURQDU\ $UWHU\
'LVHDVH LQ 3DWLHQWV 5HIHUUHG IRU 9DOYXODU +HDUW 6XUJHU\
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7BMWVMBSIFBSUEJTFBTFJT BDPNNPOJOEJDBUJPO GPSDBSEJBD
TVSHFSZ 1SFPQFSBUJWF EJBHOPTUJD DPSPOBSZ BOHJPHSBQIZ
%$"  JT SPVUJOFMZ QFSGPSNFE JO QBUJFOUT XIP VOEFSHP
WBMWVMBSIFBSU TVSHFSZ 7)4  5IJT QSBDUJDF JT ESJWFOCZ UIF
OFHBUJWF JNQBDU PG VOUSFBUFE PCTUSVDUJWF DPSPOBSZ BSUFSZ
EJTFBTF $"%  PO QFSJPQFSBUJWFBOE MPOHUFSNPVUDPNFTh 
5IF DVSSFOU "NFSJDBO $PMMFHF PG$BSEJPMPHZ 'PVOEBUJPO
BOE "NFSJDBO )FBSU "TTPDJBUJPO HVJEFMJOFT SFDPNNFOE
UIBU %$" CF QFSGPSNFE PO BMM QBUJFOUT XIP VOEFSHP
OPOFNFSHFOU 7)4 JG UIFSF BSF TZNQUPNT PG BOHJOB  MFGU
WFOUSJDVMBSEZTGVODUJPO  FWJEFODFPGJTDIFSOJB  PS GVODUJPOBM
SOJUSBM SFHVSHJUBUJPO  %$"JT BMTPSFDPNNFOEFEGPSQBUJFOUT
XJUI LOPXO IJTUPSJFT PG$"% PS IJHI QSFUFTU QSPCBCJMJUZ PG
$"% *O DPOUSBTU  GPSQBUJFOUT XJUI MPX PS JOUFSNFEJBUF QSF
UFTU QSPCBCJMJUZ PG$"%  DPSPOBSZ DPNQVUFE UPNPHSBQIJD
BOHJPHSBQIZ $5"  JT SFDPNNFOEFE  :FU UIFSF BSF OP
DSJUFSJBEFGJOJOH MPX  JOUFSNFEJBUF  BOE IJHI SJTL GPS$"%
"EEJUJPOBMMZ  UIFSF BSF OP UPPMT UP PCKFDUJWFMZ BTTFTT B QB
UJFOUhTSJTLGPSPCTUSVDUJWF$"%CFGPSF7)45IJT TUVEZ XBT
GPDVTFE PO QBUJFOUT XIP VOEFSXFOU %$" CFGPSF 7)4 
XJUIPVU LOPXO IJTUPSJFT PG$"%  BOE XJUI MPX PSJOUFSNF
EJBUFQSFUFTUQSPCBCJMJUZPG$"%5IFBJNTXFSFUP EFUFSNJOF
UIF QSFWBMFODF BOE SJTL GBDUPST BTTPDJBUFE XJUI PCTUSVDUJWF
$"% JO UIJT QPQVMBUJPO BOE UP DSFBUF B SJTL QSFEJDUJPO
OPNPHSBN UP PCKFDUJWFMZ BTTFTT QSFPQFSBUJWF SJTL GPS
PCTUSVDUJWF$"% 6MUJNBUFMZ UIJT JOGPSNBUJPOJT JOUFOEFE UP
GBDJMJUBUFBQQSPQSJBUFUSJBHFUPFJUIFSBDPSPOBSZ$5"PS%$"
CFGPSF 7)4
.FUIPET
1BUJFOUT XFSF JEFOUJGJFE GSPN UIF $PSPOBSZ $BUIFUFSJ[B
UJPO %BUBCBTFBUUIF$MFWFMBOE0JOJD1BUJFOUTXFSFJODMVEFE
JGUIFZVOEFSXFOUQSFPQFSBUJWF%$"GPSBQSJNBSZ JOEJDBUJPO
PGWBMWVMBSIFBSUEJTFBTFGSPN'FCSVBSZ   UP 0DUPCFS
  VOEFSXFOU 7)4 XJUIJO  NPOUIT PG%$"  BOE XFSF
h ZFBSTPGBHF 1BUJFOUT XFSFFYDMVEFE JGUIFZ IBE LOPXO
$"%  LOPXO JTDIFSOJBCZ TUSFTT UFTUJOH  PSDPOHFOJUBM IFBSU
EJTFBTF 1BUJFOUT XFSFBMTPFYDMVEFEJ G UIFZ VOEFSXFOU %$"
GPSBQSJNBSZ JOEJDBUJPO PGBOHJOB)PXFWFS CFDBVTFBOHJOB
DBO CF BTZNQUPNP G TFWFSF WBMWVMBSEJTFBTF  QBUJFOUT XFSF
JODMVEFE JGUIFZ VOEFSXFOU %$" GPSBQSJNBSZ JOEJDBUJPO PG
WBMWVMBSIFBSUEJTFBTFBOEIBE TZNQUPNTPGBOHJOB CVUOPUJG
UIFZ QSFTFOUFE XJUI JTDIFSOJD TZNQUPNT BOE IBE WBMWVMBS
EJTFBTF BEJTUJODUJPOEFGJOFEJO UIF$PSPOBSZ$BUIFUFSJ[BUJPO
%BUBCBTF 

Table 1
Baseline characteristics for the Entire cohort and divided According to the
presence or absence of obstructive coronary artery disease
Characteristic

Entire
Cohort
(n 5360)

Age (years)
63  14
Male
57%
27 [24 30]
Body Mass Index
(kg/m2)
Diabetes Mellitus
16%
Hypertension
50%
History of CVA or TIA
8%
History of smoking
39%
Family history of
8%
premature CAD
Hyperlipidemia
39%
Renal dysfunction
25%
Aortic Valve surgery
50%
Mitral Valve surgery
49%
Tricuspid Valve surgery
9%
Multiple Valve surgery
7%
ACE or ARB
44%
Aspirin
40%
Beta blocker
46%
Statin
35%

Obstructive CAD
(n

p Value

No
Yes
4325) (n 1035)

60  13
55%
27 [24 30]

71  11
63%
27 [24 30]

<0.001
<0.001
0.20

13%
49%
8%
39%
7%

28%
55%
10%
39%
9%

<0.001
0.003
0.04
0.89
0.12

36%
21%
47%
53%
10%
8%
43%
39%
46%
32%

52%
42%
65%
35%
4%
4%
49%
44%
45%
46%

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.002
0.38
<0.001

Comorbidities (diabetes, hypertension, hyperlipidemia, history of TIA or
stroke) deﬁned by ICD 9 Code. Renal dysfunction deﬁned as a GFR
<60 mls/min/1.73 m2 or the requirement of renal replacement therapy.
Obstructive CAD deﬁned as 50% stenosis in 1 artery.
Continuous variables expressed as mean  standard deviation or median
[interquartile range].
ACE
angiotensin converting enzyme inhibitor; ARB
angiotensin
receptor blocker; CAD coronary artery disease, CVA cerebrovascular
accident; TIA transient ischemic attack.

The presence of obstructive CAD was deﬁned as 50%
stenosis in 1 artery as graded by the physician performing
the procedure. A threshold of 50% stenosis was chosen
as the deﬁnition of obstructive CAD on the basis of the
American College of Cardiology Foundation and American
Heart Association guidelines, in which a >50% stenosis is a
class IIa recommendation for bypass in patients who undergo
noncoronary cardiac surgery.5 A threshold of 50% was
speciﬁcally chosen over the class I recommended threshold
of 70% stenosis on the basis of the goal of designing a
preoperative screening tool. Using the threshold of 50%
ensures that the risk prediction nomogram and the associated
estimated risk for CAD provide a conservative estimate when
being used to triage between CTA and DCA.
Clinical, imaging, and laboratory characteristics were obtained from the time of the DCA by querying the electronic
medical record (Epic, Verona, Wisconsin). Co-morbidities
such as diabetes, hypertension, hyperlipidemia, and stroke
were identiﬁed by International Classiﬁcation of Diseases,
Ninth Revision, coding. Glomerular ﬁltration rate was
calculated using the Cockcroft-Gault equation, and renal
dysfunction was deﬁned as a glomerular ﬁltration rate
<60 ml/min/1.73 m2 or the requirement for renal replacement
therapy. The Institutional Review Board at the Cleveland
Clinic granted approval for this research.

Continuous variables are expressed as mean  SD or as
median (interquartile range) for normal or non-normal
distributions, respectively. Student’s t test or the Wilcoxon
rank sum test was used to assess differences between groups
for continuous variables. Categorical variables were
compared using the chi-square test and are expressed as
percentages. Logistic regression was used to estimate the
odds ratios and 95% conﬁdence intervals (CIs) for predictors
of obstructive CAD. Covariates selected for multivariate
analysis included age, gender, diabetes, hypertension, history
of stroke or transient ischemic attack, smoking, family history of premature CAD, hyperlipidemia, renal dysfunction,
and the different valve surgical procedures (aortic valve,
mitral valve, tricuspid valve, or multiple valve surgery).
A nomogram to predict the risk for obstructive CAD was
constructed. Patients were randomly split in a 4:1 ratio
into derivation and validation groups. The randomization
was matched by age (5 years) and by gender. Variables
identiﬁed by multivariate regression as independent predictors of obstructive CAD were included in the nomogram.
Within the derivation group, logistic regression was used
to calculate the b coefﬁcients for each of the included
variables. These b coefﬁcients were then applied to the
validation group. The resultant model was validated by
assessing Somers’s D rank correlation between predicted
probabilities and observed responses. Then, bootstrapping
using 250 sample patients was used to penalize for possible
overﬁtting. This information was also used to estimate C
statistics and corresponding 95% CIs. The performance of
the ﬁnal model was assessed in the validation cohort and
corrected for overﬁtting. All analyses were performed using
R version 3.0.2 (R Foundation for Statistical Computing,
Vienna, Austria), and p values <0.05 were considered tol
indicate statistical signiﬁcance.
Results
We identiﬁed 5,360 patients without histories of CAD
who underwent DCA as part of preoperative evaluation for
VHS. Within the cohort, 1,035 patients (19.3%) were found
to have obstructive CAD (Table 1). Compared with patients
without obstructive CAD, those with obstructive CAD
tended to be older, were more frequently male, and had a
higher prevalence of co-morbidities, including diabetes,
hypertension, hyperlipidemia, a history of transient ischemic
attack or stroke, and renal dysfunction. Additionally,
patients with obstructive CAD more often underwent aortic
valve surgery compared with non aortic valve surgery.
Baseline characteristics stratiﬁed by speciﬁc valve
surgery are listed in Table 2. Within the cohort of patients
who underwent aortic valve surgery, the prevalence of
obstructive CAD was higher in this group compared with
those who underwent mitral, tricuspid, or multiple valve
surgery. Additionally, patients who underwent aortic valve
surgery were older than those who underwent mitral or
tricuspid valve surgery and were more often male.
In univariate analyses, age had the strongest association
with obstructive CAD (Table 3). The relation between age
and obstructive CAD is depicted in Figure 1. As expected,
the risk for obstructive CAD increased with age, but this
relation was not linear. There was a steep increase in risk

Table 2
Baseline characteristics According to valve surgery
Characteristic
Age (years)
Male
Body Mass Index (kg/m2)
Diabetes Mellitus
Hypertension
History of CVA or TIA
History of smoking
Family history of premature CAD
Hyperlipidemia
Renal dysfunction
Obstructive CAD
ACEI or ARB
Aspirin
Beta blocker
Statin

Aortic Valve
(n 2481)

Mitral Valve
(n 2285)

Tricuspid Valve
(n 200)

Multiple Valve
(n 394)

p Value

64  14
61%
29  6
21%
56%
9%
40%
8%
46%
25%
26%
45%
42%
43%
42%

60  12
57%
27  6
10%
44%
7%
38%
8%
33%
21%
14%
41.8%
37%
46%
29%

62  15
34%
28  7
18%
45%
7%
40%
7%
30%
37%
11%
42%
34%
59%
25%

65  14
42%
28  7
22%
58%
15%
43%
6%
37%
40%
10%
50%
44%
61%
34%

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.07
0.73
<0.001
<0.001
<0.001
0.01
<0.001
<0.001
<0.001

Comorbidities (diabetes, hypertension, hyperlipidemia, history of TIA or stroke) deﬁned by ICD 9 Code. Renal dysfunction deﬁned as a GFR <60 mls/min/
1.73 m2 or the requirement of renal replacement therapy. Obstructive CAD deﬁned as 50% stenosis in 1 artery.
Continuous variables expressed as mean  standard deviation or median [interquartile range].
ACE angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; CAD coronary artery disease; CVA cerebrovascular accident;
TIA transient ischemic attack.
Table 3
Univariate predictors of obstructive coronary artery disease
Predictors
Age (years)
Male
Body Mass Index (kg/m2)
Diabetes Mellitus
Hypertension
History of CVA or TIA
History of smoking
Family history of premature CAD
Hyperlipidemia
Renal dysfunction
Aortic Valve surgery
Mitral Valve surgery
Tricuspid Valve surgery
Multiple Valve surgery
ACE or ARB
Aspirin
Beta blocker
Statin

Or (95% CI)

p Value

2.65(2.43 2.89)
1.38(1.2 1.59)
1.01(0.95 1.08)
2.49(2.12 2.93)
1.23(1.08 1.41)
1.28(1.02 1.62)
1.01(0.88 1.16)
1.22(0.96 1.56)
1.92(1.68 2.21)
2.75(2.37 3.2)
2.13(1.85 2.45)
0.48(0.42 0.56)
0.42(0.3 0.57)
0.45(0.32 0.63)
1.31(1.14 1.5)
1.24(1.09 1.43)
0.94(0.82 1.08)
1.82(1.58 2.08)

<0.001
<0.001
0.72
<0.001
0.003
0.03
0.87
0.10
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.002
0.36
<0.001

Comorbidities (diabetes, hypertension, hyperlipidemia, history of TIA or
stroke) deﬁned by ICD 9 Code. Renal dysfunction deﬁned as a GFR
<60 mls/min/1.73 m2 or the requirement of renal replacement therapy.
Obstructive CAD deﬁned as 50% stenosis in 1 artery.
ACE
angiotensin converting enzyme inhibitor; ARB
angiotensin
receptor blocker; CAD coronary artery disease; CVA cerebrovascular
accident; TIA transient ischemic attack.

starting at about 50 years of age. The risk for obstructive
CAD in patients 50 years of age was 4.2%, while in patients >50 years of age, it was 23.0%. The risk for
obstructive CAD further increased with age, and in those
>65 years of age, it reached 32%. In contrast, for patients
40 years of age, the overall risk for obstructive CAD was
only 1.9%.

In addition to the association between obstructive CAD
and age, the univariate analyses identiﬁed associations
between obstructive CAD and many traditional CAD risk
factors. These risk factors included male gender, diabetes,
hypertension, hyperlipidemia, and a history of transient
ischemic attack or stroke (Table 3). Aortic valve surgery
was associated with increased odds of obstructive CAD,
whereas mitral valve, tricuspid valve, and multiple valve
surgical procedures were associated with a decreased odds
of obstructive CAD.
In multivariate analyses, age continued to have the
strongest association with obstructive (Table 4). Interestingly, within the multivariate analyses, the speciﬁc
dysfunctional valve was not associated with the prevalence
of obstructive CAD. Variables of male gender, diabetes,
hyperlipidemia, family history of premature CAD, and renal
dysfunction remained associated with obstructive CAD.
Hypertension was found to have a negative association with
obstructive CAD. There was no interaction between the
presence of hypertension and age, male gender, or therapy
with aspirin, statin, b blockers, angiotensin-converting
enzyme inhibitors, or angiotensin receptor blockers.
To devise the CAD prediction nomogram, the 5,360patient cohort was randomly divided into a 4,286-patient
derivation group and a 1,074-patient validation group.
There were no differences in the baseline characteristics
between these 2 groups (Supplementary Table 1). The
nomogram incorporated age, gender, the presence of
diabetes, hyperlipidemia, renal dysfunction, and a family
history of premature CAD (Figure 2). Hypertension was not
included in the nomogram given its negative association with
obstructive CAD. However, before excluding this variable,
the model was assessed with and without hypertension, and
no statistically signiﬁcant differences were noted. The
speciﬁc valve being operated on was also not included in the
nomogram, as this was not a signiﬁcant variable in the

Figure 2. Risk prediction nomogram. The risk for obstructive CAD is
estimated by ﬁrst calculating a patient’s risk score. The number of points
assigned to the patient’s age is noted at the right of the ﬁgure. Male gender
and a history of diabetes are assigned 3 points, renal dysfunction is assigned
2 points, and hyperlipidemia and a family history of CAD are assigned 1
point. The summed total points on the x axis correspond to a predicted risk
for obstructive CAD on the y axis. Five points correspond to a 2% risk for
obstructive CAD, 10 points to a 5% risk, 13 points to a 10% risk, and 15
points to a 17.5% risk. The bias corrected C statistic for the model is 0.765
(95% CI 0.748 to 0.782).

Figure 1. Risk for obstructive CAD by age.

Table 4
Multivariate analysis of predictors of signiﬁcant coronary artery disease
Predictors
Age (years)
Male
Body Mass Index (kg/m2)
Diabetes Mellitus
Hypertension
History of CVA or TIA
History of smoking
Family history of premature CAD
Hyperlipidemia
Renal dysfunction
Aortic Valve surgery
Mitral Valve surgery
Tricuspid Valve surgery
Multiple Valve surgery
ACE or ARB
Aspirin
Beta blocker
Statin

Or (95% CI)

p Value

2.41(2.17 2.68)
1.94(1.64 2.3)
0.99(0.9 1.08)
2.07(1.7 2.52)
0.81(0.68 0.97)
1.02(0.78 1.34)
0.98(0.84 1.16)
1.34(1.02 1.76)
1.47(1.02 2.1)
1.47(1.21 1.78)
1.36(0.47 3.96)
0.95(0.32 2.77)
0.56(0.19 1.63)
0.46(0.13 1.59)
1.16(0.98 1.37)
0.95(0.81 1.12)
0.85(0.72 1)
0.91(0.64 1.31)

<0.001
<0.001
0.79
<0.001
0.02
0.87
0.85
0.04
0.04
<0.001
0.57
0.92
0.29
0.22
0.08
0.55
0.05
0.63

Comorbidities (diabetes, hypertension, hyperlipidemia, history of TIA or
stroke) deﬁned by ICD 9 Code. Renal dysfunction deﬁned as a GFR
<60 mls/min/1.73 m2 or the requirement of renal replacement therapy.
Obstructive CAD deﬁned as 50% stenosis in 1 artery.
ACE
angiotensin converting enzyme inhibitor; ARB
angiotensin
receptor blocker; CAD coronary artery disease; CVA cerebrovascular
accident; TIA transient ischemic attack.

multivariate analysis. Age was separated into 5-year increments and assigned points weighted to corresponding
risk. Male gender and diabetes were assigned 3 points, renal
dysfunction 2 points, and hyperlipidemia and a family history of premature CAD 1 point. The total score is depicted
on the x axis and the corresponding risk for obstructive CAD
on the y axis. A total score of 13 was associated with a 10%
risk for obstructive CAD.
The ﬁnal model was ﬁrst validated for Somers’s D rank
correlation between predicted probabilities and observed

responses. Next, 250 bootstrap samples were used to estimate C statistics and corresponding 95% CIs. The C statistic
for the derivation cohort was 0.766 (95% CI 0.750 to 0.783)
and for the validation cohort 0.767 (95% CI 0.751 to 0.784).
The resulting optimism was 0.004 (95% CI 0.001 to 0.006),
which is sufﬁciently low to essentially exclude the possibility of overﬁtting. The bias-corrected C statistic was 0.765
(95% CI 0.748 to 0.782).
Discussion
This study represents the largest evaluation of patients
who underwent preoperative DCA preceding VHS to date. It
was focused on those patients in whom the guidelines
recommend either DCA or coronary CTA for preoperative
coronary assessment. As expected, this study showed
univariate associations between traditional cardiac risk
factors and obstructive CAD. However, in multivariate
analyses, there were no independent associations between
the dysfunctional valve and obstructive CAD. Therefore,
using only age, gender, and the presence or absence of risk
factors, a model was successfully constructed to predict the
risk for obstructive CAD. This model can be used to riskstratify patients who undergo preoperative evaluation
before VHS and facilitate triage to the appropriate preoperative testing. Before this investigation, there were no
available tools to objectively deﬁne risk in this population.
Within the study cohort, the observed prevalence of
obstructive CAD was 19.3%. This prevalence of obstructive
CAD is lower than in cohorts with ischemic symptoms but
concordant with other previous studies of asymptomatic
patients.6 8 In univariate and multivariate analyses, age had
the strongest association with obstructive CAD. The weight
of this association is reﬂected in the similarities between the
curves seen in Figure 1, in which risk for obstructive CAD is
plotted against age, and Figure 2, in which many traditional
risk factors are included with age.

Multiple studies have shown a correlation between
obstructive CAD and aortic valve disease.9 11 This correlation is attributed to similar pathologic processes of coronary
atheroma formation and valvular calciﬁcation.12 Conversely,
studies have shown a decreased incidence between mitral
valve disease and obstructive CAD.13 This study showed an
increased incidence of obstructive CAD in patients who
underwent aortic valve surgery and a decreased incidence in
those who underwent mitral valve surgery. However, once
these correlations were evaluated in context of the patient’s
age, they were no longer present. It is possible that the
correlations seen between different valve lesions and
obstructive CAD are the result of different valvular pathologies’ predilections to present in certain age groups and the
age-dependent nature of coronary atherosclerosis.
The nomogram in Figure 2 can be used to predict the risk
for obstructive CAD in patients who undergo DCA as a part
of a preoperative evaluation for VHS. Using readily accessible information about patient age, gender, and risk factors,
a score can be calculated and cross-referenced with the
curve to assess an estimated incidence of obstructive CAD.
A score of 10 correlates with a 5% risk for obstructive CAD,
while a score of 13 correlates with a 10% risk and a score of
15 with a 17.5% risk. Using this information, it would be
reasonable to consider a patient with a score 13 (i.e., a risk
for obstructive CAD of 10%) to be within the category of
low or intermediate risk and therefore reasonable for coronary CTA instead of DCA.
The recommendation for preoperative coronary evaluation in low- or intermediate-risk patients using coronary CTA
was ﬁrst introduced in the 2014 version of the guidelines for
valvular heart disease.4,14 By the time this occurred, the
patients in this study had undergone their VHS. However,
had they been prospectively evaluated using the nomogram
from Figure 2, and delegated to CTA if their predicted risk for
obstructive CAD was <10%, 1,501 patients (28%) could
have been triaged to preoperative coronary CTA. The
majority of these patients would have undergone VHS
without the additional risks, inconveniences, and costs of
preoperative DCA. Fewer than 150 patients (2.8% of the
total) would have had positive results on coronary computed
tomography and also required DCA. This is an acceptably
low crossover rate, and given the high sensitivity of coronary
CTA, this approach is very unlikely to result in a patient’s
going to VHS with undiagnosed obstructive CAD.15 Overall,
this approach could result in signiﬁcant reductions in patient
risk and hospital costs.13
The conclusions of this study must be interpreted within
the context of its limitations. This study was a retrospective
analysis based on a cohort from a single tertiary referral
center. We were unable to determine the type of valve
dysfunction (stenotic vs regurgitant) or the underlying cause
of the valve dysfunction (degenerative, infectious, and so
on). In particular, we were unable to speciﬁcally exclude
the patients with functional mitral regurgitation, although
presumably those with ischemic mitral regurgitation would
have been excluded on the basis of a history of CAD. Other
potential limitations include the deﬁnition of co-morbidities
on the basis of International Classiﬁcation of Diseases,
Ninth Revision, codes and a nonadjudicated deﬁnition of
obstructive CAD.
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